Calculators and Tools for Obesity Assessment

WHO BMI categories: Underweight <18.5, Normal 18.5–24.9, Overweight 25–29.9, Obesity Class I 30–34.9, Class II 35–39.9, Class III (severe) ≥40. BMI limitations: it does not distinguish fat from muscle mass; it can misclassify muscular individuals as overweight and under-diagnose obesity in those with low muscle mass. Ethnic-specific thresholds apply — Asian populations have higher cardiometabolic risk at BMI 23–27.5 (WHO consultation recommends action points at these levels). BMI should be interpreted alongside waist circumference and body composition measures.

IDF/AHA/WHO risk thresholds for waist circumference: Men — increased risk ≥94 cm (European), ≥90 cm (South Asian/Chinese/Japanese), ≥88 cm (some US guidelines use ≥102 cm for high risk); Women — increased risk ≥80 cm (European/Asian), ≥88 cm (US high risk threshold). Waist-to-height ratio >0.5 is a simple, ethnicity-independent predictor of cardiometabolic risk. Waist-to-hip ratio >0.90 (men) or >0.85 (women) indicates central obesity. These measures predict metabolic risk independently of BMI.

A deficit of 500–750 kcal/day below TDEE produces approximately 0.5–0.75 kg/week loss — safe and sustainable for most adults. Deficits >1000 kcal/day increase risk of lean mass loss, nutrient deficiency, and metabolic adaptation (reduction in RMR beyond predicted). Start with TDEE calculation, then subtract the deficit. Protein intake ≥1.2 g/kg/day during weight loss preserves lean mass. Very low calorie diets (<800 kcal/day) require medical supervision and are typically reserved for pre-surgical optimization of severe obesity.

Current guidelines (ASMBS/IFSO 2022) recommend bariatric surgery for: BMI ≥35 kg/m² regardless of comorbidities, or BMI ≥30–34.9 kg/m² with metabolic disease (T2DM, hypertension, sleep apnea, NAFLD) when lifestyle interventions have failed. Asian populations may qualify at BMI ≥27.5 with comorbidities. Procedures: sleeve gastrectomy (most common), Roux-en-Y gastric bypass (most effective for T2DM remission), and adjustable gastric banding. Average excess weight loss: 60–70% at 2 years. T2DM remission occurs in 60–80% after bypass surgery.

Obesity independently increases risk of hypertension, dyslipidemia, T2DM, sleep apnea, atrial fibrillation, and heart failure — all of which drive cardiovascular events. The ASCVD Pooled Cohort Equations incorporate BMI indirectly through its effect on cholesterol, blood pressure, and diabetes status. A 5–10% weight reduction produces clinically meaningful improvements: SBP reduction 3–5 mmHg, triglycerides −15–30%, HDL +2–5%, fasting glucose −3–8%. GLP-1 agonists (semaglutide, tirzepatide) now have demonstrated cardiovascular mortality benefit in obesity even without diabetes (SELECT trial 2023).

Healthy body fat percentage ranges by sex and age: Men — essential fat 2–5%, athletes 6–13%, fitness 14–17%, acceptable 18–24%, obese ≥25%. Women — essential fat 10–13%, athletes 14–20%, fitness 21–24%, acceptable 25–31%, obese ≥32%. Body fat is measured by DEXA (gold standard), hydrostatic weighing, air displacement plethysmography (BodPod), bioelectrical impedance (less accurate), or skinfold calipers. BMI and body fat percentage correlate but diverge significantly in muscular individuals and older adults with sarcopenic obesity.